These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23061660)

  • 21. The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead.
    Siu T; Kozina ES; Jung J; Rosenstein C; Mathur A; Altman MD; Chan G; Xu L; Bachman E; Mo JR; Bouthillette M; Rush T; Dinsmore CJ; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7421-5. PubMed ID: 21044843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
    J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
    Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
    Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
    Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
    Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
    Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
    J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
    Gerspacher M; Furet P; Pissot-Soldermann C; Gaul C; Holzer P; Vangrevelinghe E; Lang M; Erdmann D; Radimerski T; Regnier CH; Chene P; De Pover A; Hofmann F; Baffert F; Buhl T; Aichholz R; Blasco F; Endres R; Trappe J; Drueckes P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1724-7. PubMed ID: 20138510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
    Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
    J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
    Yang LL; Li GB; Yan HX; Sun QZ; Ma S; Ji P; Wang ZR; Feng S; Zou J; Yang SY
    Eur J Med Chem; 2012 Oct; 56():30-8. PubMed ID: 22944772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
    Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
    Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.